Circulation. 2022 Apr 12;145(15):e811-e838. doi: 10.1161/CIR.0000000000001056. Epub 2022 Mar 7.
In the cardio-oncology population, drug interactions are of particular importance given the complex pharmacological profile, narrow therapeutic index, and inherent risk of therapies used to manage cardiovascular disease and cancer. Drug interactions may be beneficial or detrimental to the desired therapeutic effect. Clinicians in both cardiology and oncology should be cognizant of these potential drug-drug interactions that may reduce the efficacy or safety of either cardiovascular or cancer therapies. These risks can be mitigated through increased recognition of potential drug-drug interaction, use of alternative medications when possible, and careful monitoring. This scientific statement provides clinicians with an overview of pharmacodynamic and pharmacokinetic drug-drug interactions in patients with cancer exposed to common cardiovascular and cancer medications.
在心血管肿瘤人群中，由于药物具有复杂的药理学特性、狭窄的治疗指数以及用于治疗心血管疾病和癌症的治疗方法固有风险，药物相互作用尤其重要。药物相互作用可能对所需的治疗效果有益或有害。心脏病学和肿瘤学领域的临床医生都应该意识到这些潜在的药物相互作用，这些相互作用可能会降低心血管或癌症治疗的疗效或安全性。通过增加对潜在药物相互作用的认识、在可能的情况下使用替代药物以及仔细监测，可以降低这些风险。本科学声明为临床医生提供了患有癌症的患者中常见心血管和癌症药物暴露的药物相互作用的药效学和药代动力学概述。
